Clinical trials
Adult clinical trials
Below are recruiting adult clinical trials, each written for real people, not researchers. We’re tracking 3,746 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06802913RecruitingEarly Phase 1
Inhaled melatonin for sleep problems in older adults
This trial tests a new inhaled form of melatonin to help adults aged 55 and older with insomnia fall asleep faster. It compares the inhaled melatonin to a placebo to see if it improves sleep and is safe.
Macquarie Park, New South WalesAges 55 years+ - NCT05694858RecruitingPhase 1/Phase 2
Numbing patch comparison before blood draw for eye care
This trial tests a numbing skin patch made with tiny microneedles against a standard numbing cream/patch to reduce pain before a blood draw. It may help you feel less discomfort during venepuncture before an eye procedure.
Kuala Lumpur, Kuala LumpurAges 18 years+ - NCT06634147Recruiting
Exercise program to prevent decline in hospitalized older adults
This study is testing a gentle exercise program for older adults (75+) while they are in the hospital. The goal is to see if it helps prevent loss of strength, memory, or thinking skills.
Pamplona, NavarreAges 75 years+ - NCT06788756RecruitingPhase 2/Phase 3
Testing L-Annamycin plus Cytarabine for relapsed AML
This trial tests whether the combination of two chemotherapy drugs, L-Annamycin and Cytarabine, can help adults whose acute myeloid leukemia (AML) has come back or not responded to one prior treatment. The goal is to see if this combination can lead to remission.
Birmingham, AlabamaAges 18–80 - NCT06782958Enrolling by invitationPhase 1
Safety study of FHND1002 granules in healthy adults
This trial tests a new medication called FHND1002 in healthy adults aged 18 to 45. The goal is to check its safety, how well the body tolerates it, and how it is processed. It is one of the first tests in humans.
Lanzhou, GansuAges 18–45 - NCT06786234RecruitingPhase 2
STP938 for high-risk essential thrombocythemia
This trial tests a daily pill called STP938 (dencatistat) for people with high-risk essential thrombocythemia (ET) who cannot take or have stopped responding to hydroxycarbamide. The goal is to see if STP938 can safely lower your platelet count and control the condition.
Poitiers, New AquitaineAges 18 years+ - NCT06788509Enrolling by invitationPhase 1
Continued treatment and safety monitoring after a parent study
This trial allows people who were already getting study treatment in a previous trial to keep receiving it and be monitored for safety. It is designed for those who have not had serious side effects or disease worsening.
Macquarie UniversityAges 18 years+ - NCT06783309RecruitingPhase 1/Phase 2
Testing CNP-103 for newly diagnosed type 1 diabetes
This trial tests a new study drug called CNP-103 for people ages 12-35 who were recently diagnosed (within 6 months) with stage 3 type 1 diabetes. The goal is to see if the drug can help preserve the body's ability to make some insulin, potentially slowing the need for more insulin shots.
Tucson, ArizonaAges 12–35 - NCT06787612RecruitingPhase 2
New combination for platinum-resistant ovarian cancer
This study tests a new combination treatment (ubamatamab plus another drug) for people with ovarian cancer that no longer responds to platinum chemotherapy. It could be an option if your cancer has kept growing despite prior treatment.
Birmingham, AlabamaAges 18 years+ - NCT06783114RecruitingPhase 2/Phase 3
Testing a new Botox-like injection for arm stiffness after stroke
This study tests an investigational botulinum toxin injection (YY001) to reduce muscle stiffness in the arm after a stroke. It may help you move your arm more easily and improve daily tasks.
Hefei, AnhuiAges 18–75 - NCT06789913RecruitingPhase 2
Testing RLY-2608 for growth disorders linked to PIK3CA mutations
This trial tests a new medicine, RLY-2608, that targets the specific genetic change (PIK3CA mutation) causing overgrowth conditions. It aims to see if the drug can slow or stop the growth of affected tissues.
Phoenix, ArizonaAges 2 years+ - NCT06789445RecruitingPhase 1/Phase 2
Cell therapy for inherited retinal disease (CLARICO)
This study tests a new cell therapy (OpCT-001) for adults with inherited retinal diseases that affect the light-sensing cells. It aims to see if the treatment is safe and possibly helps improve vision.
Los Angeles, CaliforniaAges 18 years+ - NCT03772561RecruitingPhase 1
Testing AZD5363, olaparib, and durvalumab for advanced solid cancers
This Phase 1 trial tests a combination of three medicines to shrink or control advanced solid tumors that are progressing or no standard options exist. It mainly focuses on safety and early signs of how well the treatment works.
Singapore, SingaporeAges 21–99 - NCT06785181Recruiting
Heart-brain health in healthy adults
This study looks at how the heart, blood vessels, and brain work together in healthy adults. It may help us understand normal body function.
San Donato Milanese, MilanoAges 18 years+ - NCT06729502Recruiting
Frailty Scale for Older Adults in the ICU
This study uses a simple picture-based scale to measure frailty in older adults (60+) who were admitted to the intensive care unit. It aims to better understand how frailty affects recovery in this setting.
Petah TikvaAges 60 years+ - NCT06681818Recruiting
New method to measure liver regrowth after surgery
This study tests a new way to measure how well your liver grows back and heals after part of it is removed. The goal is to predict and prevent complications after surgery.
Englewood, New JerseyAges 18 years+ - NCT03789383Recruiting
Living donor liver transplant and biliary complication outcomes study
This study looks at what factors lead to “biliary complications” (problems involving the bile ducts that help move bile from the liver) after an adult living-donor liver transplant. It’s aimed at people who had this specific type of transplant at the study hospital in Egypt.
AsyutAges 18–65 - NCT05219617RecruitingPhase 3
Carisbamate for frequent drop seizures in Lennox-Gastaut
This Phase 3 study tests whether carisbamate can reduce drop seizures in people with Lennox-Gastaut syndrome (LGS). It also checks whether the treatment is safe when added to existing seizure medicines.
Palo Alto, CaliforniaAges 4–55 - NCT06017765Recruiting
Mindfulness for grief after losing a loved one
This study tests whether a mindfulness program can help adults cope with intense grief after the loss of a loved one. If you have been diagnosed with Prolonged Grief Disorder and are not in other grief treatment, this may be an option for you.
Caen, CalvadosAges 18–60 - NCT06773936Enrolling by invitationPhase 2
Adding asciminib to usual care for adults with newly diagnosed Ph+ ALL
This trial tests if adding asciminib, a targeted pill, to standard treatment works better for adults newly diagnosed with a specific type of acute lymphoblastic leukemia (Ph+ ALL). It is for those who are older, or who cannot or choose not to have intensive chemotherapy.
Tucson, ArizonaAges 60 years+ - NCT06779188RecruitingEarly Phase 1
Brain stimulation to improve balance in older adults
This trial tests whether a non-invasive brain stimulation technique called theta burst TMS can improve balance and brain connectivity in adults over 65 who have had recent falls. It involves MRI scans, 4 weeks of treatment, and follow-up tests.
Houston, TexasAges 65 years+ - NCT06778863RecruitingPhase 1
A study of CLSP-1025 for adults with certain solid tumors
This trial tests a new drug called CLSP-1025 for people with advanced solid tumors that have a specific change in the p53 gene (R175H). The drug targets this change to help fight the cancer.
Scottsdale, ArizonaAges 18 years+ - NCT06780670RecruitingPhase 2/Phase 3
Comparing a new treatment to standard care for advanced prostate cancer
This study tests a new drug (AAA817) against the usual treatments for men with advanced prostate cancer that has stopped responding to a type of targeted radiation therapy (Lu-PSMA). The goal is to see if the new drug can slow the cancer's growth better than standard options.
Scottsdale, ArizonaAges 18–100 - NCT06772623RecruitingPhase 1/Phase 2
Study of telisotuzumab adizutecan plus immunotherapy for advanced lung cancer
This trial tests a new combination treatment for people with advanced non-squamous non-small cell lung cancer who haven't received prior therapy for advanced disease and don't have specific gene changes. The treatment includes an antibody-drug conjugate (telisotuzumab adizutecan) plus an immunotherapy drug (PD-1 checkpoint inhibitor) to see if it helps shrink tumors and improve outcomes.
Phoenix, ArizonaAges 18 years+
Hear when a new Adult trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for adult?
- Yes. Clin2 currently lists 3,746 recruiting adult studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a adult trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a adult trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.